Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial

Kazemi, Asma; Noorbala, Ahmad Ali; Azam, Kamal; Eskandari, Mohammad Hadi; Djafarian, Kurosh

doi:10.1016/j.clnu.2018.04.010

Cited by 369 publications

(318 citation statements)

References 27 publications

Supporting

Mentioning

280

Contrasting

Unclassified

Order By: Relevance

“…Dysbiosis and resulting inflammation via cytokine release is one proposed mechanism of MDD, and therefore a potential site for intervention. Kazemi et al conducted a doubleblind, placebo-controlled study to evaluate the effects of probiotics and prebiotics on inflammatory markers and urinary cortisol levels in patients with MDD [43]. A total of 110 patients were recruited and randomly assigned to the prebiotic group (n = 36), the probiotic group (n = 38), and the placebo group (n = 36).…”

Section: Prebiotics Probiotics Cytokines and Cortisolmentioning

confidence: 99%

“…Kazemi et al conducted a randomized, double blind, placebo-controlled study to compare the effects of probiotic and prebiotic supplementation on the BDI as a primary outcome, and the kynurenine/tryptophan ratio and tryptophan/ branched chain amino acids (BCAAs) ratio as secondary outcomes in patients with MDD [43]. A total of 81 patients were enrolled in this study and randomly assigned to probiotic group (n = 28), prebiotic group (n = 27), and placebo group (n = 26).…”

Section: Clinical and Metabolic Responses To Probiotics In Major Deprmentioning

confidence: 99%

See 1 more Smart Citation

Current Perspectives on Gut Microbiome Dysbiosis and Depression

et al. 2020

View full text Add to dashboard Cite

The human gut microbiome partakes in a bidirectional communication pathway with the central nervous system (CNS), named the microbiota-gut-brain axis.The microbiota-gut-brain axis is believed to modulate various central processes through the vagus nerve as well as production of microbial metabolites and immune mediators which trigger changes in neurotransmission, neuroinflammation, and behavior. Little is understood about the utilization of microbiome manipulation to treat disease. Though studies exploring the role of the microbiome in various disease processes have shown promise, mechanisms remain unclear and evidence-based treatments for most illnesses have not yet been developed. The animal studies reviewed here offer an excellent array of basic science research that Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.11865615. A. Capuco

show abstract

Section: Prebiotics Probiotics Cytokines and Cortisolmentioning

confidence: 99%

Section: Clinical and Metabolic Responses To Probiotics In Major Deprmentioning

confidence: 99%

Current Perspectives on Gut Microbiome Dysbiosis and Depression

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The cellulase-producing fungus F. palustris NBRC 30339 was added to the fermentation flask of S. commune to enhance ethanol production from cedar wood by degrading cellulose. Fomitopsis palustris secretes enzymes that degrade polysaccharide and causes brown rot decay in the wood [31,32]. However, the results showed almost no difference between the single and mixed cultures, probably because of an insufficient rate of cellulase secretion from F. palustris.…”

Section: Discussionmentioning

confidence: 97%

Direct Ethanol Production from Lignocellulosic Materials by Mixed Culture of Wood Rot Fungi Schizophyllum commune, Bjerkandera adusta, and Fomitopsis palustris

2019

View full text Add to dashboard Cite

The cost of bioethanol production from lignocellulosic materials is relatively high because the additional processes of delignification and saccharification are required. Consolidated bioprocessing (CBP) simultaneously uses the multiple processes of delignification, saccharification, and fermentation in a single reactor and has the potential to solve the problem of cost. Some wood-degrading basidiomycetes have lignin- and cellulose-degrading abilities as well as ethanol fermentation ability. The white rot fungus Schizophyllum commune NBRC 4928 was selected as a strong fermenter from a previous study. The lignin-degrading fungus Bjerkandera adusta and polysaccharide-degrading fungus Fomitopsis palustris were respectively added to S. commune ethanol fermentations to help degrade lignocellulosic materials. Bjerkandera adusta produced more ligninase under aerobic conditions, so a switching aeration condition was adopted. The mixed culture of S. commune and B. adusta promoted direct ethanol production from cedar wood. Fomitopsis palustris produced enzymes that released glucose from both carboxymethylcellulose and microcrystalline cellulose. The mixed culture of S. commune and F. palustris did not enhance ethanol production from cedar. The combination of S. commune and cellulase significantly increased the rate of ethanol production. The results suggest that CBP for ethanol production from cellulosic material can be achieved by using multiple fungi in one reactor.

show abstract

“…Inter-and intra-assay Coefficient of Variation (CV) for fasting blood glucose and lipid concentrations were less than 5%. Low-Density Lipoprotein Cholesterol (LDL-C) was calculated by the Friede-Wald formula: LDL-C (mg/dl) = TC -(HDL -C + TG/5) [27].…”

Section: Biochemical Analysismentioning

confidence: 99%

The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial

Haidari

Banaei-Jahromi

Zakerkish

et al. 2020

Nutr J

View full text Add to dashboard Cite

Background: Polycystic Ovary Syndrome (PCOS) is known as the most common endocrine disorder of women in reproductive ages. With the increasing prevalence of PCOS in different countries, the use of herbal medicine as an alternative treatment is growing in these patients. This study aimed to evaluate the effects of flaxseed powder supplementation on metabolic biomarkers of patients with PCOS. Methods: This randomized open-labeled controlled clinical trial was conducted on 41 patients with PCOS. The participants were randomized to take either flaxseed powder (30 g/day) plus lifestyle modification or only lifestyle modification for 12 weeks. Anthropometric and biochemical evaluations were performed for all patients at the beginning and end of the study. Results: The flaxseed group showed a significant reduction in body weight, insulin concentration, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Triglycerides (TG), high-sensitivity C-Reactive Protein (hs-CRP), and leptin and an increase in Quantitative Insulin-Sensitivity Check Index (QUICKI), High Density Lipoprotein (HDL), and adiponectin compared to the baseline (p < 0.05). Flaxseed supplementation also led to a significant reduction in insulin concentration, HOMA-IR, TG, hs-CRP, Interleukin 6 (IL-6), and leptin and an increase in QUICKI, HDL, and adiponectin compared to the control group (p < 0.05). No significant changes were observed in other parameters. Conclusions: Flaxseed supplementation plus lifestyle modification was more effective compared to lifestyle modification alone in biochemical and anthropometric variables in patients with PCOS. Trial registration: The trial protocol was approved by the Ethics Board at Ahvaz Jundishapur University of Medical Sciences and was registered at Iranian Registry of Clinical Trials (code: IRCT20120704010181N11).

show abstract

Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial

Cited by 369 publications

References 27 publications

Current Perspectives on Gut Microbiome Dysbiosis and Depression

Current Perspectives on Gut Microbiome Dysbiosis and Depression

Direct Ethanol Production from Lignocellulosic Materials by Mixed Culture of Wood Rot Fungi Schizophyllum commune, Bjerkandera adusta, and Fomitopsis palustris

The effects of flaxseed supplementation on metabolic status in women with polycystic ovary syndrome: a randomized open-labeled controlled clinical trial

Contact Info

Product

Resources

About